liver and GI disease in pregnancy
AST/ALT, bilirubin, GGT don’t change in pregnancy — any rise is pathological (ALP ↑ is placental). Diagnose by trimester + pattern: HG (T1), ICP (pruritus, bile acids >19 µmol/L), HELLP (≥20 wk, haemolysis + plt <100, usually hypertensive), AFLP (late T3, hypoglycaemia + coagulopathy + AKI). HELLP and AFLP → stabilise and deliver.
pattern recognition
| hyperemesis | ICP | HELLP | AFLP | |
|---|---|---|---|---|
| timing | T1 (resolves ~20 wk) | late T2–T3 | ≥20 wk, ~30% postpartum | late T3, occasionally postpartum |
| clinical | vomiting, >5% weight loss, dehydration | pruritus palms/soles, worse at night, no rash | RUQ/epigastric pain, nausea, ± HTN/proteinuria | N/V, abdominal pain, polyuria/polydipsia, jaundice, encephalopathy |
| AST/ALT | mild (<200) | 100s | 100s–1000s | moderate (often <500–1000) |
| bilirubin | normal/mild | normal/mild | ↑ unconjugated (haemolysis) | ↑↑ conjugated |
| discriminators | ketonuria, ↓K⁺ | bile acids >19 µmol/L | LDH ↑, haptoglobin ↓, schistocytes, plt <100 | glucose ↓, INR ↑, fibrinogen ↓, Cr ↑, NH₃ ↑, WBC ↑ |
| treatment | antiemetics, fluids, thiamine | UDCA, timed delivery | BP, MgSO₄, deliver | correct glucose/coagulopathy, deliver |
- Always exclude non-obstetric causes: viral hepatitis (A, B, C, E — fulminant in pregnancy), HSV hepatitis (anicteric, very high ALT, fever), gallstones/cholangitis, DILI, Budd–Chiari, AIH — see approach to elevated liver enzymes
- Workup: CBC + film, AST/ALT, ALP, GGT, bilirubin, INR, fibrinogen, glucose, LDH, haptoglobin, Cr, uPCR, non-fasting bile acids, viral serology, RUQ US
HELLP
- Complication of preeclampsia; 10–20% normotensive, 15% without proteinuria
- Tertiary centre; treat severe BP + magnesium sulfate; deliver (>34 wk or deteriorating → now; <34 wk stable → steroids then deliver)
- Platelets (SOGC): transfuse if <20 before vaginal, <50 before caesarean, or with active bleeding, rapid fall, or coagulopathy; recheck often — counts fall fast
- Corticosteroids to treat HELLP: not recommended (lab improvement only)
- Hepatic haematoma/rupture: severe RUQ/shoulder pain, hypotension, Hb drop → CT/US, IR/surgery
- Labs often worsen for 24–48 h postpartum, then recover within ~3–5 d
- Not improving by ~day 3, or Cr/schistocytes/thrombocytopenia disproportionate → TTP or complement-mediated HUS — see haematology in pregnancy
acute fatty liver of pregnancy
- Mitochondrial β-oxidation defect — foetal LCHAD deficiency in a subset → screen the neonate
- Swansea criteria (≥6 of 14, no other cause): vomiting, abdominal pain, polydipsia/polyuria, encephalopathy, ↑bilirubin, hypoglycaemia, ↑urate, leukocytosis, ascites/bright liver on US, ↑AST/ALT, ↑NH₃, AKI, coagulopathy, microvesicular steatosis on biopsy
- Biopsy almost never needed — don’t delay delivery for it
- Management: ICU, dextrose infusion (q1h glucose), FFP/cryoprecipitate for coagulopathy, prompt delivery after stabilisation; hepatology ± transplant centre if failure persists after delivery
- Recovery usually begins 2–3 d after delivery
Hypoglycaemia, INR >1.5, low fibrinogen, encephalopathy, and conjugated hyperbilirubinaemia point to AFLP (synthetic failure). HELLP is haemolysis + thrombocytopenia with relatively preserved synthetic function until DIC. Overlap is common — both mean delivery.
intrahepatic cholestasis of pregnancy (SOGC 2024)
- Diagnosis: pruritus (palms/soles) + non-fasting bile acids >19 µmol/L; exclude other liver disease
- Repeat bile acids + LFTs every 2–4 wk (management uses the peak level); repeat if typical symptoms + initial normal result
- UDCA 10–15 mg/kg/d in 2–3 divided doses (max 20 mg/kg/d) → modest ↓ pruritus, ↓ ALT; no ↓ composite of perinatal death, preterm birth, NICU admission (PITCHES (2019))
- Adjuncts: emollients, antihistamines; rifampicin 300–1200 mg/d for refractory cases. Dexamethasone, cholestyramine, SAMe are ineffective
- ↑ preeclampsia, GDM, preterm birth, NICU admission; stillbirth risk rises sharply at bile acids ≥100 µmol/L
| peak bile acids (µmol/L) | suggested delivery (SOGC) |
|---|---|
| 20–39 | 39⁺⁰–39⁺⁶ wk |
| 40–69 | 38⁺⁰–38⁺⁶ wk |
| 70–99 | 36⁺⁰–37⁺⁶ wk |
| ≥100 | by 36 wk (earlier if comorbidity, prior ICP stillbirth) |
- Postpartum: resolves within 1–2 (up to 4) wk; confirm at 6 wk, persistent → investigate (PBC, PSC, ABCB4)
- Recurrence 70–90%; progestin-only contraception preferred; later ↑ gallstones, hepatobiliary disease
Foetal-risk condition. Bile acids 65 µmol/L at 32 wk → UDCA, repeat bile acids q2–4 wk, plan delivery 38 wk.
nausea, vomiting, hyperemesis (SOGC 2016)
- NVP in 50–80%; HG 0.3–2% (vomiting, >5% weight loss, ketonuria, electrolyte derangement)
- Stepwise: stop iron-containing prenatals (folic acid only), small frequent meals, ginger → doxylamine–pyridoxine → dimenhydrinate/H1 antihistamine → metoclopramide or prochlorperazine/chlorpromazine → ondansetron (check QTc)
- HG admission: IV fluids (dextrose-containing after thiamine), K⁺/Mg²⁺/phosphate, thiamine before dextrose (Wernicke’s), IV antiemetics, PPI/H2RA; refractory → corticosteroids (after 10 wk) with obstetric input
- New N/V after 20 wk ≠ NVP → think HELLP, AFLP, pyelonephritis, appendicitis
- GERD common: calcium carbonate → H2RA → PPI (all acceptable)
- Cannabis hyperemesis — ask; counsel cessation
viral hepatitis in pregnancy
- HBV (SOGC): universal HBsAg screening; tenofovir (TDF) from 28–32 wk if HBV DNA >200,000 IU/mL; infant HBIG + vaccine within 12 h; breastfeeding fine, including on TDF — see viral hepatitis
- CASL 2025 starts earlier: TDF or TAF as soon as possible and no later than the second trimester; screen HBsAg every first trimester; continue up to 12 weeks postpartum (longer if family planning continues), then ALT every 4 weeks × 3 months and at 6 months; infant HBIG + vaccine as soon as possible after birth, doses 2–3 by 6 months, test at 1–4 months after the last dose; breastfeeding on TDF/TAF allowed
- HCV: universal anti-HCV screening each pregnancy (SOGC); no DAA in pregnancy/breastfeeding — treat postpartum; avoid scalp electrodes/foetal blood sampling; no CS indication; breastfeed unless nipples cracked/bleeding; test infant (RNA at ≥2 months)
- HEV: high maternal mortality in T3 — consider in travellers from endemic areas
evidence
- PITCHES (2019) — n=605; UDCA didn’t reduce composite perinatal outcome (stillbirth, preterm birth, NICU); modest itch improvement
- Ovadia, Lancet. 2019 — IPD meta-analysis; stillbirth risk not ↑ until bile acids ≥100 µmol/L (HR ~30)
Prepared 2026-10-28. Not yet verified — check every number against the sources.